Research programme: epithelial sodium channel inhibitors - Parion Sciences

Drug Profile

Research programme: epithelial sodium channel inhibitors - Parion Sciences

Alternative Names: P-1055

Latest Information Update: 08 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Parion Sciences
  • Class
  • Mechanism of Action Epithelial sodium channel-antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bronchiectasis; Chronic obstructive pulmonary disease; Cystic fibrosis

Most Recent Events

  • 04 Jun 2015 P 1055 licensed to Vertex Pharmaceuticals worldwide
  • 05 May 2014 Parion Sciences reacquires rights to sodium channel inhibitors for pulmonary indications from Gilead Sciences
  • 15 Aug 2007 Preclinical trials in Bronchiectasis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top